The Enhanced In Vivo Activity of the Combination of a MEK and a PI3K Inhibitor Correlates with [18F]-FLT PET in Human Colorectal Cancer Xenograft Tumour-Bearing Mice

Emma J. Haagensen; Huw D. Thomas; Ian Wilson; Suzannah J. Harnor; Sara L. Payne; Tommy Rennison; Kate M. Smith; Ross J. Maxwell; David R. Newell

doi:10.1371/journal.pone.0081763

Loading metrics

Open Access

Peer-reviewed

Research Article

The Enhanced In Vivo Activity of the Combination of a MEK and a PI3K Inhibitor Correlates with [¹⁸F]-FLT PET in Human Colorectal Cancer Xenograft Tumour-Bearing Mice

Emma J. Haagensen,

Affiliation Newcastle Cancer Centre, Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, Newcastle University, Framlington Place, Newcastle-upon-Tyne, United Kingdom
⨯
Huw D. Thomas,

Affiliation Newcastle Cancer Centre, Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, Newcastle University, Framlington Place, Newcastle-upon-Tyne, United Kingdom
⨯
Ian Wilson,

Affiliation Newcastle Cancer Centre, Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, Newcastle University, Framlington Place, Newcastle-upon-Tyne, United Kingdom
⨯
Suzannah J. Harnor,

Affiliation Newcastle Cancer Centre, Northern Institute for Cancer Research, School of Chemistry, Bedson Building, Newcastle University, Newcastle, United Kingdom
⨯
Sara L. Payne,

Affiliation Newcastle Cancer Centre, Northern Institute for Cancer Research, School of Chemistry, Bedson Building, Newcastle University, Newcastle, United Kingdom
⨯
Tommy Rennison,

Affiliation Newcastle Cancer Centre, Northern Institute for Cancer Research, School of Chemistry, Bedson Building, Newcastle University, Newcastle, United Kingdom
⨯
Kate M. Smith,

Affiliation Newcastle Cancer Centre, Northern Institute for Cancer Research, School of Chemistry, Bedson Building, Newcastle University, Newcastle, United Kingdom
⨯
Ross J. Maxwell,

Affiliation Newcastle Cancer Centre, Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, Newcastle University, Framlington Place, Newcastle-upon-Tyne, United Kingdom
⨯
David R. Newell

* E-mail: herbie.newell@ncl.ac.uk

Affiliation Newcastle Cancer Centre, Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, Newcastle University, Framlington Place, Newcastle-upon-Tyne, United Kingdom
⨯

The Enhanced In Vivo Activity of the Combination of a MEK and a PI3K Inhibitor Correlates with [¹⁸F]-FLT PET in Human Colorectal Cancer Xenograft Tumour-Bearing Mice

Emma J. Haagensen,
Huw D. Thomas,
Ian Wilson,
Suzannah J. Harnor,
Sara L. Payne,
Tommy Rennison,
Kate M. Smith,
Ross J. Maxwell,
David R. Newell

Published: December 10, 2013
https://doi.org/10.1371/journal.pone.0081763

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Cancers and neoplasms
Is the Subject Area "Cancers and neoplasms" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Positron emission tomography
Is the Subject Area "Positron emission tomography" applicable to this article?

Thanks for your feedback.
Biomarkers
Is the Subject Area "Biomarkers" applicable to this article?

Thanks for your feedback.
Colorectal cancer
Is the Subject Area "Colorectal cancer" applicable to this article?

Thanks for your feedback.
MAPK signaling cascades
Is the Subject Area "MAPK signaling cascades" applicable to this article?

Thanks for your feedback.
Phosphorylation
Is the Subject Area "Phosphorylation" applicable to this article?

Thanks for your feedback.
Pharmacokinetics
Is the Subject Area "Pharmacokinetics" applicable to this article?

Thanks for your feedback.